{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Defined as percentage of patients achieving a partial response or better by International Myeloma Working Group (IMWG) standard criteria:\n\nIMWG: Complete Response (CR): negative immunofixation on the serum and urine, no soft tissue plasmacytomas and \\<5% plasma cells in the bone marrow; stringent CR: CR+normal free light chain ratio, no clonal cells in bone marrow by immunohistochemistry or immunofluorescence; Very Good Partial Response: serum and urine M-protein detected by immunofixation but not electrophoresis, \\>90% in serum M-protein+urine, M-protein level \\<100 mg/24hour; Partial Response (PR): ≥50% decrease of serum and M-protein, 24 hour urinary M-protein decrease by ≥90% or \\<200 mg/24hour.","groups":[{"description":"INDUCTION (28-day cycles for 8 cycles):\n\n* VELCADE 1.3 mg/m2 subcutaneously (SC) days 1, 8 and 15\n* Cyclophosphamide 300 mg/m2 orally (PO) days 1, 8 and 15\n* Dexamethasone 40 mg PO days 1,8 and 15\n\nMAINTENANCE (28-day alternating cycles until stopped for toxicity, relapse or death):\n\n* Odd cycles (9, 11, 13, etc.) lenalidomide 10 mg PO days 1-21\n* Even cycles (10, 12, 14, etc.) VELCADE 1.3 mg/m2 SC days 1, 15\n\nVelcade: Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles \\[10,12,14, etc.\\]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until","id":"OG000","title":"Velcade, Cyclophosphamide, Revlimid"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 8 months","title":"Overall Response Rate (ORR) During Induction Therapy","type":"PRIMARY","unitOfMeasure":"percentage of participants"}